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PENILAIAN RAWATAN HASILAN PNEUMONIA ARUHAN KOMUNITI 
DAN KOS PENYAKIT 
DAN 
PEMBANGUNAN MODEL MORTALITI  
 
 
ABSTRAK 
 
Pneumonia aruhan komuniti (CAP) adalah punca mortaliti dan kematian utama di 
seluruh dunia termasuk Malaysia. Pengenalan perbezaaan dalam keputusan 
perubatan dan kos di antara hospital universiti dengan hospital umum (GH) boleh 
membantu perkembangan dalam rawatan pneumonia dan membantu pasukan 
kesihatan melakukan perkhidmatan perubatan dengan tepat and berkesan.  
Perkembangan dan pengesahan model mortaliti pneumonia yang mana berdasarkan 
faktor risiko yang boleh didapati pada masa kemasukan hospital boleh membantu 
mengenalpasti pesakit yang berisiko tinggi dan merawat mereka dengan tepat.  
Perawatan CAP adalah mahal dan kos adalah berhubungan dengan kepanjangan 
tinggal di hospital (LOS). Oleh kerana itu, pengesahan factor risiko dari peningkatan 
LOS boleh menyebabkan penurunan kos perawatan CAP. Maka, penyelidikan ini 
bertujuan pertamanya membandingkan keputusan perawatan dan kos di antara 
hospital universiti dengan GH; Hospital umum dan keduanya mengembang kan 
model mortaliti pneumonia di Hospital Pulau Pinang dan Hospital Universiti Sains 
Malaysia; ketiganya, mengenalpasti faktor risiko bagi peningkatan LOS. Satu 
penyelidikan restrospektif secara pemerhatian telah dijalankan di antara pesakit 
dewasa CAP yang dimasukkan ke Hospital Pulau Pinang dengan Hospital Universiti 
Sains Malaysia dari 1hb Januari 2007 sampai 31hb Disember 2008. Secara umumnya 
tidak tardapat sebarang perbezaan hasitan rawatan diantara Hospital Universiti Sains 
Malaysia dan Hospital Pulau Pinang terdapat perbezaaan jelas di antara kos di 
HUSM dan HPP. Penemuan nenunjukkan bahawa HPP memberi keputusan 
xxvii 
 
perubatan yang serupa dengan kos perubatan pneumonia yang lebih rendah 
berbanding dengan HUSM.  Model mortaliti pneumonia mengandungi 
pembolehubah bebas termasuk: kekeliruan, kadar pernafasan lebih daripada 30 
pernafasan per minit, tekanan darah sistolik kurang daripda 90  mmHg,  glukosa 
darah rawak lebih daripada 13 mmol/l, ventilasi mekanik, kemasukan ICU, penyakit  
seiring lebih daripada atau sama dengan tiga,  Hgb < 8 g/dl, urea > 11 mmol/l, dan 
albumin < 30 g/dl. Kepekaan model adalah 69.6 %, kekhususan (specificity) adalah 
98.0%, Positive Predictive Value (PPV) adalah 83.6 %, Negative Predictive Value 
(NPV) adalah 95.8 % dan keluasan dibawah keluk (AUC) adalah 0.839. Terdapatnya 
bebas faktor berikut termasuk peningkatan LOS, komplikasi, umur, penyakit seiring 
dengan pneumonia, kelambatan penggunaan antibiotik lebih daripada lapan jam, dan 
memulakan perawatan dengan satu antibiotik. 
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EVALUATION OF COMMUNITY ACQUIRED PNEUMONIA TREATMENT 
OUTCOMES AND COST OF ILLNESS  
AND 
DEVELOPMENT OF MORTALITY MODEL 
 
ABSTRACT 
Community acquired pneumonia (CAP) is a major cause of morbidity and mortality 
worldwide including Malaysia. Identification of the differences in the outcome and 
cost between a university hospital and a general hospital (GH) could lead to the 
development of pneumonia interventions and guide the health team to accurately 
perform and administrate health care services effectively. The development and 
validation of the pneumonia mortality model, which is easily accessible at the time of 
admission can, identify patients who are at risks, and treat them appropriately. 
Treatment of CAP is costly and the cost is related to the length of hospital stay 
(LOS).Therefore, identification of the risk factors of increase the LOS is lead to 
decrease the cost of CAP treatment. Therefore, this study aims firstly to compare the 
treatment outcome and cost between a university hospital and a general hospital; 
secondly, to develop pneumonia mortality model in Hospital Pulau Pinang (HPP) 
and validation the model in Hospital Universiti Sains Malaysia(HUSM); thirdly, to 
identify the risk factors of increase the LOS. A retrospective observational study was 
conducted among the adult patients with CAP who admitted to the Penang General 
HPP and to the HUSM from 1st January 2007 to 31st December 2008. Generally, 
there is no significant difference between the outcome between the HUSM and HPP. 
However, there is a significant difference between the cost between the HUSM and 
HPP. The findings show that the HPP provided a similar treatment outcome at lower 
CAP treatment cost in comparison to HUSM. The pneumonia mortality model 
composed of the following independent variables: confusion, respiratory rate > 30 
xxix 
 
breaths/min, systolic blood pressure < 90 mmHg, random blood glucose > 13 
mmol/l, mechanical ventilation, ICU admission, concomitant disease more than or 
equal 3, Hgb < 8 g/dl, urea > 11 mmol/l, albumin < 30 g/dl. The model sensitivity is 
69.6 %, specificity is 98.0 %, Positive Predictive Value (PPV) is 83.6 %, Negative 
Predictive Value (NPV) is 95.8 % and area under the curve (AUC) is 0.839. There 
were the following independent risk factors that significantly increase the length of 
hospital stay; presences of the complications, elderly, presence of the concomitant 
diseases associated with pneumonia, delay administration of antibiotics more than 8 
hours and start the treatment with single antibiotic. It was concluded that the HPP 
provided a similar treatment outcome at lower CAP treatment cost in comparison to 
HUSM. The validated model composed of easily accessible variables at the time of 
admission can, identify patients who are at risks, and treat them appropriately. 
 
 1 
CHAPTER 1 
INTRODUCTION 
 
1.1. Problem statement and rational of study 
  Pneumonia is the inflammation and consolidation of lung tissue due to an infectious 
agent (Marrie TJ, 1994). Depending on the onset of signs and symptoms of pneumonia, it is 
divided to two types; community acquired pneumonia and nosocomial acquired pneumonia 
or hospital acquired pneumonia. If the signs and symptoms of pneumonia occurred outside 
the hospital or within 48 hours of the admission to the hospital it is called community 
acquired pneumonia. If the signs and symptoms of the pneumonia occurred inside the 
hospital or 48 hours after the admission to the hospital it is  called nosocomial acquired 
pneumonia or hospital acquired pneumonia (Bartlett JG et al., 1995; Bergogne-Berezin et 
al .,1995 ; Craven, D et al ., 1995 ; Craven, D et al ., 1998 ; Garner, J  et al., 1988; Coalson, 
J. 1995 ; Bauer, T et al., 2000 ; Chastre, J  et al ., 2002 ; Kollef, M. 1999b). Mandel LA 
2004 stated that the community acquired pneumonia is the common type of pneumonia. 
Community acquired pneumonia is characterized by cough, cough with sputum, fever, 
chills, chest pain, anorexia, headache, vomiting, nausea, myalgia, sore throat, arthralgia, 
abdominal pain, diarrhea, hemoptysis, dyspnea and fatigue (Fine et al., 1999;  Marrie et 
al.,1989 and Metlay et al., 1997b) 
Community acquired pneumonia (CAP) is a major cause of morbidity and mortality 
worldwide, CAP among the main ten causes of admission to the hospital and mortality 
worldwide. CAP is associated with significant utilization of health care resources. 
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It is costly and lead to restricted daily activity (Adams PF and Marano MA,  1995; 
Graves, E. J. & Gillum, B. S. 1996; Lacroix et al., 1989; Marston et al., 1997; Woodhead  
et al., 1987; Guest JF and Morris 1997;  Almiral et al., 1993; Marrie 1990, Fine et al., 
1996; BTS,  2001; BTS, 2009"Lim et al.,  2009"; Niderman MS et al., 2001; Makela et al., 
1993; Tsirgiotis E et al., 2000; Jin Y et al., 2003; Whittle J et al., 1998; Metlay et al., 
1997b; Birnbaum HG 2001; Almirall et al., 2000; Bartlet JG et al., 1998; Lutifiyya MN et 
al., 2006; Bauer TT et al., 2005 ) 
Pneumonia represented one of the 10th leading causes of hospitalization and deaths 
in Malaysia during 1996-2007 (Ministry of Health, Malaysia, 1996, 1997, 1998, 1999, 
2000, 2001, 2002b, 2003, 2004, 2005b, 2006b and 2007) 
Table 1.1   Ranking of the pneumonia as one of the top causes of hospitalization 
and death in Malaysia 
Year Cause of hospitalization Cause of death due to pneumonia 
1996 5th (6.47%) 8th (4.17%) 
1997 5th (6.58%) 8th (4.33) 
1998 5th (6.51%) 7th (4.76%) 
1999 4th (6.76%) 7th (4.83%) 
2000 4th (6.69%) 8th (4.69%) 
2001 5th (6.61%) 7th (4.98%) 
2002 5th (6.35%) 6th (5.11%) 
2003 5th (6.73%) 6th (5.32%) 
2004 5th (6.83%) 6th (5.58%) 
2005 5th (6.98%) 6th (5.30%) 
2006 4th (7.30%) 5th (5.81%) 
2007 4th (7.38%) 5th (7.43%) 
 
 
 3 
Pneumonia like other infectious diseases that the people seeking the treatment either in 
university or general hospitals. A general hospital deals with most of the services that 
people need for their medical care and/or their surgical care. Many general hospitals do a 
lot of complicated surgery such as cardiac surgery. Most of the general hospitals are 
considered as a secondary care. University hospitals provide more specialized services such 
as transplant services. A university hospital contains more advanced technology. University 
hospitals focused also in medical education, training of the medical students and research. 
Seeking treatment at a university hospital is costly than a general hospital (lezzoni et al., 
1990; Zimmerman et al., 1993; Blumenthal et al., 1997; Ayanian and weissman 2002; 
Polanczyk et al., 2002; Taylor et al., 1999). A comparison of outcome between different 
types of hospitals is very necessary to the policy makers (Hofer T et al., 1996; Hartz AJ, 
1989). There are few published studies world wide that compared the university hospitals 
versus others types of hospitals but most of these studies focused on the comparison the 
quality of care. Few studied compared the outcome like length of hospitalization and 
mortality (Lave JR et al., 1996; Siegel RE. et al., 2000; Polanczyk et al., 2002; Rosenthal  
et al., 1997). There is a gap in the literature regarding to investigate that the general 
hospitals can provide a comparable outcome of treating pneumonia with lower costs. 
Treatment of community acquired pneumonia is costly (Fine et al., 2000; Nathan et al., 
2006; Barlow et al 2003; Whittle et al., 1998; Lave et al., 1996; Guest et al., 1997; Halm et 
al., 2001; Glibert et al., 1998) .  
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Increase the length of hospital stay is increase the total cost of treating community 
acquired pneumonia. It was reported that the following factors cause increase the length of 
hospital stay such as the concomitant diseases associated with community acquired 
pneumonia, complications of treating community acquired pneumonia, severity of 
community acquired pneumonia, anemia, hypoxemia, level of albumin, delay of 
administration of antibiotics more than eight hours from the time of admission to the 
hospital, in appropriate selection of the antibiotics in the treatment of community acquired 
pneumonia, performance of the culture (Niderman et al., 1998; Lave et al., 1996; Fine et 
al., 1997; Fine et al., 1996; Fine et al., 1999; Fine et al., 1993;  Hartz et al., 1996; 
Wingarten et al.,  1994; Fine et al., 2000; Runciman et al., 2002; Halm et al.,  2001; 
Nathan et al., 2006; Gleason et al., 1999; Meehan et al., 1997; Frei et al., 2006; Battleman 
et al., 2002; Houck et al., 2004; Rubin et al.,  2001; Graff et al., 2002; Farr et al.,  1991; 
Bauer et al.,  2005; Menéndez et al.,  2003; Weingarten et al.,  1996). 
The recent community acquired pneumonia management guidelines recommended 
that the previous models used in severity-of-illness scores, such as the CURB-65 and 
Pneumonia Severity Index model (PSI); can be used to decide whether the community 
acquired pneumonia patient treated as inpatient or as outpatient (American Thoracic society 
2007 " Mandell et al., 2007" ; Infectious Diseases Society of America 2007 " Mandell et 
al., 2007"; British Thoracic Society 2009 "Lim et al.,  2009").  
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1.2. Significance of the study 
 
 Since the application of the pharmacoeconomic studies in 1978, few publications 
were reported regarding pneumonia, to date there is no published study had been 
performed in Malaysia to evaluate the cost of CAP treatment.  
 There is a gap in the literatures, there is a worldwide lack in studies evaluation and 
compared the outcome and cost of treating pneumonia between a university 
hospitals and a general hospitals to investigate whether the general hospitals can 
provide a comparable outcome of treating pneumonia with lower costs. Therefore, 
this study compares the outcome and cost of treating pneumonia between a 
university hospital and a general hospital in Malaysia. 
 Identification of the differences in the outcome and cost between a university 
hospital and a general hospital (GH) could lead to the development of pneumonia 
interventions and guide the health team to accurately perform and manage health 
care services effectively. 
 Identification of the risk factors that cause increase the length of hospital stay can 
help to decrease the total cost of treating of community acquired pneumonia. 
 The development and validation of the pneumonia mortality model which are easily 
accessible at the time of admission can identify patients who are at risks, and treat 
them appropriately. 
 
 
 
 6 
1.3. Hypothesis of the Study 
 
 H1: There are significant differences of the characteristics, treatment outcome and 
direct cost between a Hospital Universiti Sains Malaysia (HUSM) and a Pulau 
Penang Hospital  (HPP). 
 H2: There are risk factors associated with a significant increase in the risk of 
pneumonia related death in Malaysian inpatients. 
 H3:  There is a risk factors are associated with a significant increase in the length of 
hospital stay in HUSM and HPP 
 
 
 
1.4. Objectives of the study 
 
1.4.1 General objectives 
1. Evaluation of pneumonia treatment outcomes and cost of illness in HUSM versus HPP. 
2. Development of pneumonia mortality model.  
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1.4.2 Specific objectives 
1. To compare the sociodemographic characteristics, concomitant diseases with pneumonia, 
signs and symptoms of pneumonia, chest radiograph findings and laboratory findings, 
distribution of microorganisms in blood and sputum, pneumonia severity index (PSI), 
CURB-65 and distribution of antibiotics prescribed in HUSM versus HPP. 
2. To compare the outcome parameters measures included length of hospital stay (LOS), 
fever clearance time, resolution of signs and symptoms, duration of antibiotics therapy in 
the ward, readmission within one month, complications and 30-day mortality in HUSM 
versus HPP. 
3. To compare the cost of illness, cost parameters included cost of LOS, laboratory and 
clinical investigations, antibiotics, drug administration, non antibiotics and total costs of 
treating CAP in HUSM versus HPP. 
4. Identification of the risk factors that increase the length of hospital stay in both hospitals 
HUSm and HPP. 
5. Development of pneumonia mortality model in HPP. 
6. Write the model equation. 
7. Validation of the model in HUSM. 
8. Compare the validated pneumonia mortality model with other models such as; PSI, 
CURB-65 and CRB-65 models in terms of calculate the sensitivity, specificity, Positive 
Predictive Value (PPV), Negative Predictive Value (NPV) and area under the curve (AUC) 
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1.5.  Research questions  
1. What is the difference of  the sociodemographic characteristics, concomitant diseases 
with pneumonia, signs and symptoms of pneumonia, chest radiograph findings and 
laboratory findings, distribution of microorganisms in blood and sputum, pneumonia 
severity index (PSI), CURB-65 and distribution of antibiotics prescribed in HUSM versus 
HPP? 
2. What is the difference of the outcome parameters measures included length of hospital 
stay (LOS), fever clearance time, resolution of signs and symptoms, duration of antibiotics 
therapy in the ward, readmission within one month, complications and 30-day mortality in 
HUSM versus HPP? 
3. What is the difference of the cost of illness; cost parameters included cost of LOS, 
laboratory and clinical investigations, antibiotics, drug administration, non antibiotics and 
total costs of treating CAP in HUSM versus HPP? 
4. What are the risk factors that increase the length of hospital stay in both hospitals HUSM 
and HPP? 
5. What is the pneumonia mortality model equation? 
6. What is the difference between the validated pneumonia mortality model with other 
models such as; PSI, CURB-65 and CRB-65 models in terms of calculate the sensitivity, 
specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV) and area 
under the curve (AUC)? 
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CHAPTER 2 
LITERATURE REVIEW 
2.1. Definition of community acquired pneumonia 
         Community-acquired pneumonia (CAP) is defined as that type of pneumonia when 
the signs and symptoms occurred before the admission to the hospital or within the two 
days of admission to the hospital (American Thoracic society 2007 " Mandell et al., 2007" ; 
Infectious Diseases Society of America 2007 " Mandell et al., 2007"; British Thoracic 
Society 2009 "Lim et al.,  2009"; Bartlett JG et al., 1995; Bartlett JG et al., 1998; Metlay JP 
et al., 1997; Smith PR, 2001) 
 
2.2.  Epidemiology & Incidence of community acquired pneumonia 
    Community acquired pneumonia is a major cause of morbidity and mortality 
worldwide. CAP within the top ten causes of admission to the hospital worldwide. (Adams 
PF and Marano MA,  1995; Graves, E. J. & Gillum, B. S. 1996; LaCroix et al., 1989; 
Marston et al., 1997; Woodhead  et al., 1987; Guest JF and Morris 1997;  Almiral et al., 
1993; Marrie 1990, Fine et al., 1996; BTS,  2001; BTS, 2009"Lim et al.,  2009"; Niderman 
MS et al., 2001; Makela et al., 1993; Tsirgiotis E et al., 2000; Jin Y et al., 2003; Whittle J 
et al., 1998; Metlay et al., 1997b; Birnbaum HG 2001; Almirall et al., 2000; Bartlet JG et 
al., 1998; Lutifiyya MN et al., 2006; Bauer TT et al., 2005 )  
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British Thoracic society, 2009 reported that the incidence of Community acquired 
pneumonia was 0.5 to 1.1 % (Lim et al., 2009). 
Adult community-acquired pneumonia is a serious, life-threatening illness that 
affects more than 3 million people each year and accountable for more than half a million 
annual hospital admissions in the United States alone (Lynch JP, 1992 ) . 
In US, each year there are more than 900 000 cases of community acquired 
pneumonia occur in the United States, accounting for nearly 3% of all hospital admissions 
(National Center for Health Statistics: Washington, 1992). 
Pneumonia is a major cause of morbidity and mortality in UK. It is cause over 10% 
of all deaths (66,581 deaths in 2001), the majority of which occur in the elderly (BTS, 
2001). 
In Japan, according to the Japanese Respiratory Society (2000), community 
acquired pneumonia is one of the major cause of morbidity and mortality in Japan. It is the 
fourth leading cause of death, and from 57 to 70 persons per 100,000 populations died per 
year of this disease in the last decade (The Japanese Respiratory Society, 2000). 
In Hong Kong, according to the Department of Health, Government of the Hong 
Kong Community acquired pneumonia (CAP) is one of the major causes of morbidity and 
mortality (Annual Report, Department of Health, and Government of the Hong Kong 
2003). 
  In Thailand, according to the Thailand Ministry of Public Health (1998) Pneumonia 
is one of the most infectious disease and one of the top causes of the admission to the 
hospital and the ministry reported that the incidence is approximately 1.5 per 1000 
population (Ministry of Public Health. Thailand, 1998)  
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  In Malaysia, according to the Ministry of Health Malaysia (MOH), Pneumonia 
represented one of the 10th leading causes of hospitalization and deaths in Malaysia 
through 1995-2009 (Ministry of Health, Malaysia, 1995- 2007) 
  
2.3.  Signs, symptoms and laboratory findings of community acquired pneumonia 
A prospective observational study by Song et al., 2008 of 955 cases of adult CAP in 
14 tertiary care hospitals in eight Asian countries (South Korea, China, Taiwan, Hong 
Kong, India, Singapore, Vietnam and The Philippines), it was reviewed all the cases 
admitted to the medical centers between January 2002 and December 2004, it was found 
that 92.8 % of the CAP patients were had cough at the time of admission to the hospitals; 
88.1 % were had purulent sputum, 62.5 % were had chest pain and 10.7 % were mentally 
altered. It was found also that 9.3 % of CAP patients were admitted to the hospitals with 
respiratory rate more than 30 breaths per minute; 6.9 % were admitted with pulse rate more 
than or equal to 125 beat per minute, 5.4 % were admitted with temperature more than or 
equal to 40 0C or less than 350C and 3 % of the patients were admitted with systolic blood 
pressure less than 90 mmHg. It was found that 66.7 % of the patients were admitted with 
elevated white blood cells; 19.4 % of the patients were admitted with abnormal blood urea 
nitrogen; 9.2 % were admitted with abnormal serum sodium, 8.9 5 were admitted with 
glucose level more than or equal to 250 mg per deciliter and 6.9 % of the cases were 
admitted with arterial pH less than 7.35 %. 
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A prospective observational study by Ngeow et al., 2005 of 926 adult cases of adult 
CAP in 12 medical centers in Asia (Beijing, Shanghai, Hong Kong, Seoul, Taipei, 
Bangkok, Manila, Kuala Lumpur, Petaling Jaya, Singapore, Jakarta, Surabaya), it was 
reviewed all the cases admitted to the medical centers between October 2001 and 
December 2002, it was found that 100 % of the CAP patients were had cough at the time of 
admission to the hospitals; 96.9 % were had fever, 83.9 % were had crepitations; 59.6 % 
were had malaise; 55.1 % were had dyspnea; 43.5 % were had rhonchi; 19 % were had 
chills; 8.5 % were had chest pain; 23.9 % were had wheezing and other symptoms were 
found in many cases i.e. diarrhea.   
Bartlet JG et al., 1995; Fine et al., 1999;  Marrie et al.,1989 and Metaly et al., 
1997b, Kothe et al.,2008 reported that the signs and symptoms such as cough, sputum 
production either with blood or without blood, fatigue , fever, chills, chest pain, sweating, 
tachycardia, tachypnea and other signs and symptoms is different from one patient to 
another, and it depends on the age of the patient, immunity status of the patient and the 
severity of the community acquired pneumonia whether severe or no. 
A multicenter prospective study conducted by Kothe et al., 2008 among 2,647 
adult's patients in 10 clinical centre's in Germany between March 2003 and October 2005. 
It was found that the majority of the patients were admitted with cough, fever, purulent 
sputum, dyspnea and pleuritic pain. While few patients were admitted with confusion ( 5.2 
% of the 1298 adults patients age less than 65 years old and 16.4 % among 1349 elderly 
patients). 
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2.4  Concomitant diseases with pneumonia 
A prospective observational study by Ngeow et al., 2005 of 926 adult cases of adult 
CAP in 12 medical centers in Asia (Beijing, Shanghai, Hong Kong, Seoul, Taipei, 
Bangkok, Manila, Kuala Lumpur, Petaling Jaya, Singapore, Jakarta, Surabaya), it was 
reviewed all the cases admitted to the medical centers between October 2001 and 
December 2002, it was found that the diabetes mellitus (DM) was the most common 
concomitant diseases and represented 14.4 % of the total cases, followed by chronic 
obstructive pulmonary disease (COPD) 13.6 %, congestive heart failure 7.8 % , asthma 7.2 
%, renal diseases 4.9 %, liver diseases 2.9 %, and others concomitant diseases 21.9 %. 
A prospective observational study by Song et al., 2008 of 955 cases of adult CAP in 
14 tertiary care hospitals in eight Asian countries (South Korea, China, Taiwan, Hong 
Kong, India, Singapore, Vietnam and The Philippines), all the cases admitted to the 
medical centers between January 2002 and December 2004 were reviewed, it was found 
that the percentage of the patients were admitted with concomitant diseases was 69.9 %, 
bronchopulmonary diseases was the most common concomitant diseases and represented 
29.9% of the total cases, followed by cardiovascular diseases 19.9 %, neoplastic disorder 
11.7 %, liver diseases 4.4 %, renal diseases 4.1 % and hyposplenia 0.7 %. 
A prospective study conducted by LOH et al., 2004 of 108 cases of adult CAP in 
urban-based university teaching hospital in Malaysia. It was found that the percentage of 
the patients admitted with concomitant diseases was 59.3 %. It was found that the 
percentage of the patients admitted with one concomitant disease was 45.4 %; the 
percentage of the patients admitted with two concomitant diseases was 50.9 % and the 
percentage of the patients admitted with three concomitant diseases was 3.7 %. 
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A prospective study by Liam CK et al., 2001 of 127 cases of community acquired 
pneumonia 12 years old or older admitted to the University Malaya Medical Centre 
between August 1997 and May 1999. It was found that the percentage of the patients were 
admitted with concomitant diseases was 59.9 %. It was found that the diabetes mellitus 
(DM) was the most common concomitant diseases and represented 19.7 % of the total 
cases, followed by chronic obstructive pulmonary disease (COPD) 18.9 %, cardiac diseases 
7.9 %, renal diseases 3.1 % and others. 
A 12 months prospective follow up study conducted by Menendez R et al., 2003 on 
four public hospitals one of them is a university referral teaching hospital and three is 
general hospitals in Valencia, Spain. Among 425 community acquired pneumonia patients 
admitted to the four hospitals, 229 CAP patients were admitted to the teaching hospital 
(hospital A), 73 CAP patients were admitted to the first general hospital (hospital B), 58 
CAP patients were admitted were admitted to the second general hospital (hospital C) and 
65 CAP patients were admitted to the third general hospital (hospital D). It was found that 
32, 41, 31, 34 chronic obstructive pulmonary disease (COPD) were associated with the 
CAP cases in the four hospitals prospectively. Followed by cardiac diseases (33, 18, 26 and 
23 cases); liver disease (5, 4, 7 and 8 cases); central nervous disease (15, 11, 15 and 19 
cases) and renal disease (5, 3, 9 and 6 cases) were associated with the CAP patients in the 
four hospitals prospectively. 
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A prospective study conducted by Reechaipichitkul W et al., 2005 among the 
patients 15 years or older was admitted to a university hospital in Khon Kaen Thailand 
between January 2001 and December 2002. It was found that the percentage of the patients 
were admitted with concomitant diseases was 87 %. It was found that the cardiovascular 
diseases was the most common concomitant diseases and represented 23.6 % of the total 
cases, followed by diabetes mellitus 17.7 %, autoimmune disease 13.4 %, renal disease 
11.4 %, neurological disease 9.4 %, hematological disease 8.3 %, chronic obstructive lung 
disease 5.5 %, asthma 3.1 % and cirrhosis 2.4 %. 
A cross sectional study was conducted by Reechaipichitkul W and  Pisprasert V. 
2004 between January 1999 and December 2001 among 383 patients diagnosed with 
community acquired pneumonia. Among 105 cases; it was found that the diabetes mellitus 
was the most common concomitant diseases and represented 25.5 % of the total cases, 
followed by cardiovascular disease 15.2 %, hematologic disease 14.3 %, chronic renal 
failure 13.3 % and other concomitant diseases. 
Kornum et al., 2007 on the population cohort study on 29,000 adult's patients with 
pneumonia admitted to the northern Denmark. It was found that 2,931 patients admitted 
with DM type 2. It was found that the percentage of the patients admitted without any co 
morbidities was 28% among diabetes patients and 43 % among non diabetes patients. It 
was found that the percentage of the patients admitted with one or two co morbidities was 
46 % among diabetes patients and 40 % among non diabetes patients. It was found that the 
percentage of the patients admitted with three or more co morbidities was 18% among 
diabetes patients and 16 % among non diabetes patients. 
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A retrospective study conducted by Kuraishi NY et al., 1992 between July 1987 and 
December 1990 on the patient's age 12 years or older diagnosed with community acquired 
pneumonia to the King Fahd Specialist Hospital in Al-Qassim Saudi Arabia. It was found 
that among 567 of the cases that diagnosed with community acquired pneumonia cases, 
53.7 % of the patients were admitted with concomitant diseases i.e. 24.9 %  DM;  10.7 % 
asthma; 11.4 % cardiovascular diseases; 12.7 % COPD; 10.1 neurological disorders, 7.8 % 
liver diseases; 5.5 renal failure and others. 
An observational study conducted by Irfan M et al., 2009 on the Aga Khan 
University Hospital in Pakistan among 329 adult patients admitted with community 
acquired pneumonia between January 2002 and August 2003. It was found that the 
percentage of the patients were admitted to the hospital with asthma was 8.2%; 45.60 % 
with cardiovascular diseases; 30.16 % with DM; 9.40 % with neurological diseases; 5.2 % 
with chronic renal failure; 3.6 % with chronic liver disease. 
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2.5.  Diagnosis of community acquired pneumonia and radiological findings  
There microorganisms can enter to the lung by three routes: inhalation, via blood 
stream, and aspiration or from an extrapulmonary site of infection (DeLong PA,Kotloff 
RM, 2000; Ward PA, 1996; Brandtzaeg P, 1995; Standiford TJ, 1997 and Cunha BA, 2001)  
Diagnosis of community acquired pneumonia is based on the laboratory 
investigations, signs and symptoms, blood culture, sputum culture and radiographic 
findings, chest x-ray is very important to make the accurate diagnosis of community 
acquired pneumonia (American Thoracic society 2007 " Mandell et al., 2007" ; Infectious 
Diseases Society of America 2007 " Mandell et al., 2007"; British Thoracic Society 2009 
"Lim et al.,  2009"; American Thoracic Society, 2001" Niderman et al., 2001" ). Canadian 
Community-Acquired Pneumonia Working Group 2000 stated that the chest X-ray, 
laboratory investigation and physical examination are reliable to confirm the diagnosis of 
community acquired pneumonia (Mandel LA 2000). 
A prospective study conducted by LOH et al., 2004 of 108 cases of adult CAP in 
urban-based university teaching hospital in Malaysia. It was found that the percentage of 
the patients with one lobe infiltrate was 41.7 %; 30.6 %.were found with two lobes 
infiltrate; 27.8 %.were found with three lobes infiltrate; 20 %.with pleural effusion. 
A prospective observational study by Song et al., 2008 of 955 cases of adult CAP in 
14 tertiary care hospitals in eight Asian countries (South Korea, China, Taiwan, Hong 
Kong, India, Singapore, Vietnam and The Philippines), all the cases admitted to the 
medical centers between January 2002 and December 2004 were reviewed, it was found 
that the percentage of the patients admitted with pleural effusion was 15 %. 
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A multicenter prospective study conducted by Kothe et al., 2008 among 2,647 
adult's patients in 10 clinical centre's in Germany between March 2003 and October 2005. 
It was found that the percentage of the patients admitted with pleural effusion was 12.6%. 
among 1298 adults patients age less than 65 years old and  18.3 % among 1349 elderly 
patients. 
A population based study conducted by Bartolome et al., 2004 of community 
acquired pneumonia in Barceolana, Spain among 14 years patients or older. Off 
134community acquired pneumonia patients treated as inpatients between December 1993 
and November 1995. It was found that the percentage of the patients admitted with pleural 
effusion was 13.4 %. It was that the percentages of the patients admitted with multilobar 
was 9.7%.   
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2.6. Etiology of community acquired pneumonia 
Marston et al., 1997 on their study stated that they are many etiology causes of 
pneumonia such as bacteria, fungi and viruses.  Bartlett JG et al 1998 reported that one of 
the causes of community acquired pneumonia in hospitalized patients was viruses and it 
causes around 15% of the total causes.  Bartlett JG et al., 2000 found that Influenza virus is 
the most common cause of pneumonia in the civilian population. 
File et al., 2004; Reimer LG 2000 and Marrie 2001 found that the Streptococcus 
pneumoniae causes around 75 % of the total causes of community acquired pneumonia 
cases, also they found that the pneumonia cause was known only of few cases about 30 % 
cases .Infectious Disease Society of America (2000) stated that Streptococcus pneumonia is 
the cause of 66% of the bacteremic pneumonia cases (Infectious Disease Society of 
America 2000 " Bartlett et al., 2000" 
A multicenter prospective study conducted by Kothe et al., 2008 among 2,647 
adults patients in 10 clinical centre's in Germany between March 2003 and October 2005. It 
was found that the pathogens causes of community acquired pneumonia was detected in 
271/1298 adults patients age less than 65 years old and in 268 /1349 elderly patients. It was 
found that Streptococcus pneumoniae was the most frequently isolated pathogen and 
represented 42.1% of the cases in the adults patients age less than 65 years old  and  43.3 % 
of the cases in the elderly patients; followed by  Legionella spp. ( 16.6 % in adults and 17.5 
% in elderly); Gram-negative bacilli  (3.7 %  in adults and 7.1 % in the elderly); 
Staphylococcus aureus  (1.5 % in adults and 2.2 % in the elderly); Haemophilus influenza 
(4.8 % in adults and 3.4 % in elderly); Chlamydia pneumonia ( 1.1 % in adults); 
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Mycoplasma pneumonia ( 14 % in adults and 0.7 % in elderly); Influenza virus A ( 5.9 % % 
in adults and 14.9% in elderly) 
 A prospective study by Liam CK et al., 2001 of 127 cases of community acquired 
pneumonia 12 years old or older admitted to the University Malaya Medical Center 
between August 1997 and May 1999.  It was found that the etiological diagnosis done in 
41.7% of the cases.  It was found that the Klebsiella pneumoniae was the most frequently 
isolated pathogen and caused 10.2% of all the cases, followed by Streptococcus 
pneumoniae (5.5%), Haemophilus influenzae (5.5%), Mycoplasma pneumoniae (3.9%) and 
Pseudomonas aeruginosa (3.9%). It was concluded that the microorganisms of the 
hospitalized CAP patient's in Malaysia different from that reported in the western countries, 
in western countries it was reported that the Streptococcus pneumonia was the most 
common cause of CAP (Marrie et al., 1989; File et al., 2004; Reimer LG 2000 and Marrie 
2001). It was found that the gram-negative bacilli were more frequently isolated in older 
patients and in those with co morbidity. 
A prospective study conducted by Loh et al., 2004 of 108 cases of adult CAP in 
urban-based university teaching hospital in Malaysia. It was found that 40% had positive  
sputum cultures; 20% had positive  blood cultures.. It was found that the percentage of 
Klebsiella pneumonia 17.8%; Mycobacterium tuberculosis 15.1%; Acinetobacter species; 
4.1%; Pseudomonas species. 2.7% and Enterobacter species (2.7%).  
 
 
 
 
 
